Ranbaxy Announces Improved Business Standards and Quality Assurance Initiatives

     Ranbaxy Announces Improved Business Standards and Quality Assurance
                                 Initiatives

  PR Newswire

  TOKYO, May 22, 2013

TOKYO, May 22, 2013 /PRNewswire/ -- Ranbaxy Laboratories Limited (hereafter,
Ranbaxy), a subsidiary of Daiichi Sankyo Co., Ltd. (hereafter, Daiichi
Sankyo), announced on May 22 the actions that Ranbaxy has taken in recent
years to address past conduct under prior management

(
http://www.daiichisankyo.com/media_investors/media_relations/press_releases/index.html
).

Daiichi Sankyo continues to support Ranbaxy in its efforts to address and
correct the conduct of the past which led to the investigations by the U.S.
Department of Justice ("DOJ") and the U.S. Food and Drug Administration
("USFDA"). These efforts include significant changes to Ranbaxy's management,
culture, operations and compliance.

Daiichi Sankyo believes that certain former shareholders of Ranbaxy concealed
and misrepresented critical information concerning the U.S. DOJ and FDA
investigations. Daiichi Sankyo is currently pursuing its available legal
remedies and cannot comment further on the subject at this time.

About Daiichi Sankyo Co., Ltd. Listed: Code No.: 4568, First Section of Tokyo,
Osaka and Nagoya Stock Exchanges President and CEO: Joji Nakayama

Contact: Noriaki IshidaCorporate Officer & Vice President Corporate
Communications Department Daiichi Sankyo Co., Ltd. Tel: +81-3-6225-1126
e-mail: kondo.toshiya.cj@daiichisankyo.co.jp

http://www.daiichisankyo.com/

Website: http://www.daiichisankyo.com
 
Press spacebar to pause and continue. Press esc to stop.